AR-sen-ik trye-OX-ide 
Absorption: IV administration results in complete bioavailability.
Distribution: Arsenic is stored in liver, kidney, heart, lung, hair and nails.
Metabolism/Excretion: Converted from pentavalent arsenic to trivalent arsenic by arsenate reductase and further converted by methyltransferases in the liver. Methylated arsenic is excreted in urine.
Half-life: Unknown.
Contraindicated in:
Use Cautiously in:
CV: COMPLETE HEART BLOCK, TORSADE DE POINTES, QT interval prolongation, atrial arrhythmias.
Derm: dermatitis.
Endo: hyperglycemia, hypoglycemia.
F and E: acidosis, hypocalcemia, hyperkalemia, hypokalemia, hypomagnesemia.
GI: abdominal pain, ↑liver enzymes, constipation.
GU: ↓fertility (males), renal failure.
Hemat: differentiation syndrome, DISSEMINATED INTRAVASCULAR COAGULATION, NEUTROPENIA, THROMBOCYTOPENIA, anemia, leukocytosis.
MS: back pain, arthralgia, bone pain, neck pain, limb pain, myalgia.
Neuro: ENCEPHALOPATHY (INCLUDING WERNICKE'S ENCEPHALOPATHY), POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME (PRES), fatigue, headache, insomnia, weakness.
Resp: hypoxia, dyspnea, pleural effusion.
Misc: MALIGNANCY, fever, hypersensitivity reactions, infection/sepsis.
Drug-Drug:
Newly Diagnosed Low-Risk APL
Relapsed or Refractory APL
5 yr): Induction — 0.15 mg/kg once daily until bone marrow remission (not to exceed 60 doses); Consolidation — starting 3–6 wk after completion of induction; 0.15 mg/kg once daily for 25 doses over a period of 5 wk.IV Administration:
50 days or occurs on 2 consecutive cycles, assess remission status with marrow aspirate. If molecular remission, decrease dose to 0.10 mg/kg. NDC Code*